← Back to Analyst Consensus 
SNY Hold
Sanofi
Current Price —
Implied Upside —
Analysts 31
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jan 16, 2026 | UBS | downgrade | Buy → Neutral | $0 | 54% |
| Jan 6, 2026 | Barclays | downgrade | Overweight → Equal-Weight | $0 | 53% |
| Dec 9, 2025 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Dec 8, 2025 | JP Morgan | downgrade | Overweight → Neutral | $0 | 55% |
| Sep 8, 2025 | Morgan Stanley | upgrade | Equal-Weight → Overweight | $58 | 54% |
| Sep 2, 2025 | Deutsche Bank | upgrade | Hold → Buy | $0 | 57% |
| Aug 8, 2025 | JP Morgan | upgrade | Neutral → Overweight | $0 | 55% |
| Mar 21, 2025 | Goldman Sachs | initiate | — → Neutral | $65 | 54% |
| Jul 26, 2024 | Argus Research | maintain | Buy → Buy | $60 | 54% |
| Jan 23, 2024 | Morgan Stanley | initiate | — → Equal-Weight | $55 | 54% |
| Mar 27, 2023 | Argus Research | maintain | — → Buy | $60 | 54% |
| Aug 12, 2022 | Deutsche Bank | upgrade | Sell → Hold | $0 | 57% |
| Sep 27, 2021 | SVB Leerink | upgrade | Market Perform → Outperform | $0 | — |
| Jan 15, 2021 | Deutsche Bank | initiate | — → Sell | $0 | 57% |
| Mar 11, 2020 | Goldman Sachs | upgrade | Neutral → Buy | $0 | 54% |
| Feb 19, 2020 | Argus Research | maintain | — → Buy | $56 | 54% |
| Feb 11, 2020 | SVB Leerink | initiate | — → Market Perform | $0 | — |
| Jan 6, 2020 | JP Morgan | upgrade | Neutral → Overweight | $0 | 55% |
| Dec 6, 2019 | Barclays | downgrade | Equal-Weight → Underweight | $0 | 53% |
| Sep 23, 2019 | Guggenheim | upgrade | Neutral → Buy | $0 | 52% |
| Sep 3, 2019 | Bernstein | initiate | — → Outperform | $52 | 52% |
| Dec 14, 2018 | Morgan Stanley | initiate | — → Equal-Weight | $0 | 54% |
| Nov 8, 2018 | Argus Research | maintain | Buy → Buy | $50 | 54% |
| Nov 1, 2018 | Barclays | upgrade | Underweight → Equal-Weight | $0 | 53% |
| Sep 10, 2018 | B of A Securities | upgrade | Neutral → Buy | $0 | 53% |
| Aug 24, 2018 | Argus Research | maintain | Buy → Buy | $48 | 54% |
| Aug 10, 2018 | Citigroup | upgrade | Neutral → Buy | $0 | 54% |
| Jan 23, 2018 | Barclays | downgrade | Equal-Weight → Underweight | $0 | 53% |
| Nov 15, 2017 | Barclays | upgrade | Underweight → Equal-Weight | $0 | 53% |
| Aug 30, 2017 | HSBC | upgrade | Reduce → Hold | $0 | 53% |
| Apr 6, 2017 | Argus Research | initiate | — → Buy | $50 | 54% |
| Sep 23, 2016 | Piper Sandler | initiate | — → Neutral | $0 | 54% |
| May 12, 2016 | Barclays | upgrade | Equal-Weight → Overweight | $0 | 53% |
| May 3, 2016 | HSBC | downgrade | Buy → Hold | $0 | 53% |
| Dec 10, 2015 | Exane BNP Paribas | downgrade | Neutral → Underperform | $0 | 52% |
| Dec 1, 2015 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $0 | 54% |
| Nov 9, 2015 | Bryan Garnier | downgrade | Buy → Neutral | $0 | — |
| Nov 9, 2015 | UBS | downgrade | — → Neutral | $0 | 54% |
| Nov 9, 2015 | Bernstein | downgrade | Outperform → Market Perform | $0 | 52% |
| Mar 17, 2015 | Leerink Swann | upgrade | Market Perform → Outperform | $0 | — |
| Oct 29, 2014 | Deutsche Bank | downgrade | Buy → Hold | $78 | 57% |
| Oct 29, 2014 | Jefferies | downgrade | Buy → Hold | $0 | 52% |
| Oct 29, 2014 | Barclays | downgrade | Overweight → Equal-Weight | $0 | 53% |
| Oct 29, 2014 | B of A Securities | downgrade | Buy → Neutral | $0 | 53% |
| Oct 28, 2014 | Deutsche Bank | downgrade | Buy → Hold | $0 | 57% |
| Jul 28, 2014 | MainFirst Bank AG | upgrade | — → Outperform | $0 | — |
| Jan 23, 2014 | Citigroup | downgrade | Buy → Neutral | $0 | 54% |
| Jan 9, 2014 | S&P Capital IQ | downgrade | Buy → Hold | $0 | — |
| Jan 6, 2014 | JP Morgan | downgrade | Overweight → Neutral | $0 | 55% |
| Nov 18, 2013 | Kepler Cheuvreux | upgrade | Hold → Buy | $0 | — |
Price Target Trend
Jul 8, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
0y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days